Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management

Hills, A. P., Byrne, N. M., Lindstrom, R. C., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,526

Inflammation and metabolic disorders

Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760

Macrophage plasticity and polarization: in vivo veritas

Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335

Alternative activation of macrophages

Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

Obesity

Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757

Inflammatory Mechanisms in Obesity

Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754

Insulin resistance as risk factor for the development of type 2 diabetes mellitus: a systematic approach

Schmiedt, R. A., Tiucă, R. A., Tilinca, R. M., Custură, L. M., Deteșan, O., Bacso, B. I., Abalasei, B. L., Bell, A. C., Streza, M. A., & Tilinca, M. C. (2021) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2021-0033 · Cited by 3

Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes

Lyu, Y. S., Lee, H., Kim, K., Hong, S., & Park, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02917-z · Cited by 2

Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation

Deng, B., Kireev, V. A., Melentyeva, K. V., Kovalenko, I., & Pakhomov, O. V. (2020) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo30.01.034 · Cited by 2

Effect of ipragliflozin on metabolic syndrome components and non-alcoholic fatty liver disease

Petunina, N. A., Эдуардовна, Т. М., & Кузина, И. А. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-305-310 · Cited by 2

Mitochondrial Diabetes Treated With a Sodium-Glucose Co-Transporter 2 Inhibitor

Hamasaki, H. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem627 · Cited by 2

Antidiabetic agents: Do they hit the right targets?

Zhao, Y., Zhang, X., Liang, H., & Wang, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0030 · Cited by 2

The Possible Associations between Tauopathies and Atherosclerosis, Diabetes Mellitus, Dyslipidemias, Metabolic Syndrome and Niemann–Pick Disease

Fryncel, A., Madetko‐Alster, N., Krępa, Z., Kuch, M., & Alster, P. (2024) · Diagnostics · doi:10.3390/diagnostics14161831 · Cited by 2

Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors

KHAKDE, S., Jawaid, H., Yasmin, F., Ali, M. B., & REHMAN, A. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03221-6 · Cited by 2

Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus

Каретникова, В. Н., Альбертовна, Х. А., Kochergina, A. M., Осокина, А. В., Gruzdeva, O. V., Golubovskaia, D. P., & Барбараш, О. Л. (2022) · Kardiologiia · doi:10.18087/cardio.2022.12.n1838 · Cited by 2

Grifola frondosa polysaccharide Ameliorates Inflammation and Insulin Resistance by Regulating Macrophage Polarization of liver in Type 2 diabetes mellitus RatsPreprint

Zou, P., Li, X., Wang, L., She, Y., Xiao, C., Yang, P., Qian, X., Luo, P. F., & Wei, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.21.595247 · Cited by 2

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study

Greco, S., Monda, V. M., Valpiani, G., Napoli, N., Crespini, C., Pieraccini, F., Marra, A. R., & Passaro, A. (2023) · Biomedicines · doi:10.3390/biomedicines11082292 · Cited by 1

Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use

Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1

Macrophages in Inflammation, Insulin Resistance, and Therapeutic Targets: Exploring the Potential of Graptophyllum pictum

Mohammed, N., Fatchiyah, F., Djati, M. S., Rifa’i, M., & Rahayu, S. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100344 · Cited by 1

Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study

Caturano, A., Galiero, R., Simeon, V., Acierno, C., Nilo, D., Marrone, A., Trotta, M. C., Vetrano, E., Sardu, C., Russo, V., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104284 · Cited by 2

Glucose Disposal Rate: A Novel Measure of Insulin Resistance Associated With Myocardial Fibrosis and Incident Heart Failure

Bukhari, S., Kwapong, Y. A., Yanek, L. R., Michos, E. D., Lima, J. A. C., Post, W. S., Taub, C. C., Sharma, K., Mukherjee, M., Freed, B. H., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047908 · Cited by 1

Dapagliflozin Attenuates Severity of Atherosclerosis through Manufacturing Energy-Crisis to Inhibit Ferroptosis of Macrophage

Li, Z., Jia, J., Hu, H., Qiao, S., Chen, J., Li, G., Yu, Q., Xu, S., Kang, L., & Xu, B. (2022) · Annals of Hematology & Oncology · doi:10.26420/annhematoloncol.2022.1399 · Cited by 1

The Influence of Leptin Resistance on the Development of Childhood Obesity

Cho, S., & Batchelder, H. (2023) · Journal of Student Research · doi:10.47611/jsrhs.v12i2.4339 · Cited by 1

THE INFLUENCE OF OVERWEIGHT AND INFLAMMATION OF PERIODONTAL TISSUES ON THE ACTIVITY OF MARKER ENZYMES OF MACROPHAGES POLARIZATION IN THE ORAL FLUID OF PRIMARY SCHOOL-AGED CHILDREN

Onyschenko, A. V., Шешукова, О. В., & Akimov, O. Y. (2020) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2020-4-158-356-360 · Cited by 1

Novel interventional therapies to improve cardiovascular risk in women with polycystic ovary syndrome

Javed, Z. (2018) · Repository@Hull (Worktribe) (University of Hull)

Dapagliflozin attenuates severity of atherosclerosis through manufacturing energy-crisis to inhibit ferroptosis of macrophagePreprint

Li, Z., Jia, J., Hao, H., Qiao, S., Chen, J., Li, G., Qi, Y., Sun, X., Kang, L., & Xu, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1892237/v1

Standard and innovative options in the treatment of insulin resistance

Metelski, J., Krauze-Kuc, K., Metelska, A., Sereda, D., & Nieścior, H. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.041

Medical therapy

Senn, J., & Fischli, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00014-6

Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha

Srivastava, V., Sarkar, S., Tripathy, R., Pattanayak, C., & Das, M. C. (2023) · Global Journal of Medical Pharmaceutical and Biomedical Update · doi:10.25259/gjmpbu_23_2023

Estado inflamatorio en el infarto agudo de miocardio, su impacto en el remodelado ventricular y nuevas dianas terapéuticas

Moreno, A., Rodriguez-Granillo, A. M., & de la Hoz, R. P. (2023) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v91.i5.20669

Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research

夏, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142429

Therapeutic effect of Gliflozins in Nonalcoholic Hepatic Steatosis

Salto, A. M., & Estrín, M. A. (2023) · SCT Proceedings in Interdisciplinary Insights and Innovations. · doi:10.56294/piii2023149

Pharmacotherapy of obesity and metabolic syndrome. Focus on sodium-glucose cotransporter type 2 inhibitors

Abramov, V. V., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2407-04

Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis

Bari, S., Rahman, A., Hossen, M. A., & Saif‐Ur‐Rahman, K. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100229

Additional file 1 of Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study

Lee, Y.-B., Kim, D. H., Kim, S. M., Kim, N. H., Choi, K. M., Baik, S. H., Park, Y. G., Han, K., & Yoo, H. J. (2020) · Figshare · doi:10.6084/m9.figshare.12478970

Empagliflozin as an Alternative to Metformin for Antipsychotic‐Related Weight Gain: Double‐Blind Randomized Controlled Trial

Dolati, A., Ahmadimoghaddam, D., Zamanirafe, M., Rezaie, S., Khazaie, S., Mehrpooya, M., & Doostizadeh, M. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70047 · Cited by 1

The Potential Role of SGLT2 Inhibitors in Cushing's Disease

Coelho, A. I., Vale, C., Leite, A. R., Borges‐Canha, M., Neves, J. S., & Leite-Moreira, A. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70914

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298

Role of insulin resistance in atherosclerosis: underlying mechanisms and emerging stem cell-based therapeutic strategies

Zhang, Q., Chen, Y., Wang, D., Pereira, S., & Kurtyk, M. J. B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1951400

Longitudinal Improvement in Waist-to-Height Ratio During SGLT-2 Inhibitor Therapy Within a Structured Multidisciplinary Care Model: A Prospective Real-World Cohort Study

Kılıç, S., Ayaz, E. Y., Turkoglu, A. K., Salmanoğlu, M., Arslan, A., & Ulu, M. S. (2026) · Metabolites · doi:10.3390/metabo16110811

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 512

GLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.

Liang, X., Naoto, N., Nagashimada, M., Zhuge, F., Yinhua, N., Chen, G., Mayoux, E., Kaneko, S., & Tsuguhito, O. (2017) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University)

SGLT2 inhibition by empagliflozin promotes fat browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice

冠良, 陳. (2018) · The Japan Endocrine Society

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., Sakai, Y., Kaneko, S., & Ota, T. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000783 · Cited by 109

SGLT2 inhibitors modulate inflammation by altering macrophage metabolism and decreasing monocyte platelet aggregates 3256

Safa, B. I., Oakes, J. M., Simmons, J. D., Kirk, L. A., Olson, E., Bailin, S. S., Gabriel, C. L., Luther, J. M., Koethe, J. R., Kalams, S. A., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf283.1074